To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Atazanavir/Ritonavir as Effective as Lopinavir/Ritonavir in HIV Treatment-Naive Patients
URL: http://www.pslgroup.com/dg/226C92.htm
Doctor's Guide
August 1, 2008

NEW YORK -- August 1, 2008 -- In HIV treatment-naïve patients, atazanavir/ritonavir (A/R) QD shows similar antiviral efficacy to lopinavir/ritonavir (L/R) BID, according to a study published early online in the August 2 edition of The Lancet.

The authors of the CASTLE study recommend that once-daily A/R should be a first-line treatment option for these patients as it has a number of advantages over the currently recommended twice-daily L/R.

Professor Jean-Michel Molina, Hopital Saint-Louis, Paris, France; Graeme Moyle, MD, Chelsea and Westminster Hospital, London, United Kingdom; and colleagues did a study of 883 antiretroviral-naïve, HIV infected patients.

Patients were randomised to receive A/R 300/100 mg QD (n = 440) or L/R 400/100 mg BID (n = 443). Both regimens were in combination with tenofovir/emtricitabine 300/200 mg QD. The percentage of patients with viral load <50 copies/mL was measured at 48 weeks.

The researchers found that 78% of patients receiving A/R and 76% of those receiving L/R had achieved the target viral load <50 copies/mL] by week 48. CD4 cell counts increased by 203 cells/mcL in the A/R group and by 219 cells/mcL in the L/R group. In both groups, 6% of patients experienced treatment failure by the end of the study; 2 patients developed resistance mutations to treatment in the A/R group compared with none in the L/R group. Serious adverse events occurred in 12% of A/R patients and 10% of L/R patients. However, fewer patients in the A/R group compared with the L/R group experienced treatment-related diarrhoea (2% vs 11%) and nausea (4% vs 8%). Jaundice was seen in 4% of patients in the A/R group, while none was observed in the L/R group. Increases in bilirubin were seen in 34% of patients in the A/R group but in less than 1% of patients in the L/R group. "In treatment-naïve patients, atazanavir/ritonavir once-daily demonstrated similar antiviral efficacy to lopinavir/ritonavir twice daily, with less gastrointestinal toxicity but with a higher rate of hyperbilirubinaemia," the authors wrote. The authors added that the results of this study support the use of once-daily A/R as a recommended first-line treatment option, with a number of patient benefits over the currently recommended ritonavir-boosted twice-daily lopinavir for the treatment of HIV-infected antiretroviral-naïve patients. SOURCE:[ The Lancet

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.